Zydus Lifesciences Limited — Updates, 26-04-2025: Press Release

The USFDA concluded a surveillance inspection at Zydus' API Unit in Dabhasa, Gujarat, revealing six observations, none related to Data Integrity. The company is optimistic about addressing these observations efficiently. This development underscores Zydus' ongoing commitment to regulatory compliance and operational integrity. Investors should monitor how effectively the company manages these findings, as it may impact operational timelines and regulatory relations. The company’s proactive approach to resolving the inspection results could signal a stable operational outlook moving forward.